Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct;14(4):999-1017.
doi: 10.1007/s13311-017-0563-6.

Wellness and the Role of Comorbidities in Multiple Sclerosis

Affiliations
Review

Wellness and the Role of Comorbidities in Multiple Sclerosis

Brandon P Moss et al. Neurotherapeutics. 2017 Oct.

Abstract

Multiple sclerosis (MS) is a demyelinating and neurodegenerative disorder of the central nervous system, for which disease modifying therapies (DMTs) are the mainstay treatment approach to reduce inflammatory disease activity and slow worsening disability. In addition to conventional pharmacologic therapy, there is growing interest in the use of lifestyle strategies to support wellness and mitigate disease-related complications in MS. This interest stems from a growing appreciation of the role of certain comorbidities and lifestyle factors on disease activity, disability, mortality, and overall quality of life. While the current literature is not conclusive, there is evidence to suggest a potential role for vitamin D supplementation, tobacco smoking cessation, routine exercise, a plant-based, anti-inflammatory diet, and maintenance of emotional well-being as adjunct therapies to DMTs. In addition to DMTs, lifestyle strategies should be emphasized as part of a management plan focused on overall health and well-being.

Keywords: Lifestyle medicine; Multiple sclerosis; Obesity; Psychiatric comorbidities; Vascular comorbidities; Wellness.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014–1021. doi: 10.1212/WNL.0000000000002469. - DOI - PMC - PubMed
    1. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–1024. doi: 10.1212/WNL.0000000000000768. - DOI - PMC - PubMed
    1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–952. doi: 10.1056/NEJM200009283431307. - DOI - PubMed
    1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52:61–76. doi: 10.1016/j.neuron.2006.09.011. - DOI - PubMed
    1. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Medical Econ. 2013;16:639–647. doi: 10.3111/13696998.2013.778268. - DOI - PubMed